Nanomedicine(s) under the microscope.
By R. Duncan, R. Gaspar. Molecular Pharmaceutics, 2011
946 citations recorded by the source corpus.
Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable of delivering new diagnostics, treatments for unmanageable diseases, and opportunities for tissue repair or highly dangerous nanoparticles, nanorobots, or nanoelectronic devices that will wreak havoc in the body. The truth lies firmly between these two extremes. Rational design of "nanomedicines" began almost half a century ago, and >40 products have completed the complex journey from lab to routine clinical use. Here we critically review both nanomedicines in clinical use and emerging nanosized drugs, drug delivery systems, imaging agents, and theranostics with unique properties that promise much for the future. Key factors relevant to the design of practical nanomedicines and the regulatory mechanisms designed to ensure safe and timely realization of healthcare benefits are discussed.
Subfields: Biomaterials, Biomedical Engineering
View Paper: https://www.semanticscholar.org/paper/549ee1ba99344abbcefdd9b9475ae4aa30b8333f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
Citations in the corpus
- Techniques for physicochemical characterization of nanomaterials (2013, background): “The emerging field of nanomedicine utilizes nanomaterials to improve diagnosis, prevention and treatment of diseases (Duncan and Gaspar, 2011).”
- Contrast agents for molecular photoacoustic imaging (2016, background): “reproducibility, purification, and quantification of homogeneous, well-defined NPs remains challenging.(62) Details of common synthesis routes for all nanostructures and nanomaterials demonstrated for PAI can be found in Supplementary Notes 2 and 3.”